Publications

Buerger AN, Massarsky A, Russell A, Zoghby N, Hirn C, Mucs D, et al. 2023. Evaluation of chemical grouping workflows for flavor inhalation risk assessment: Selected furan moiety-containing chemicals as a case study. Comp Tox 26(May):100269; doi: 10.1016/j.comtox.2023.100269.

Meek ME, Wikoff D. 2023. The need for good practice in the application of mechanistic constructs in hazard and risk assessment. Toxicol Sci 194(1):13-22; doi: 10.1093/toxsci/kfad039. PMID: 3707944.

Kaurani P, Hindocha AD, Jayasinghe RM, Pai UY, Batra K, Price C. 2023. Effect of addition of titanium dioxide nanoparticles on the antimicrobial properties, surface roughness and surface hardness of polymethyl methacrylate: A systematic review. F1000Res 12:577; doi: 10.12688/f1000research.130028.1.

Wheeler MW. 2023. An investigation of non-informative priors for Bayesian dose-response modeling. Regul Toxicol Pharmacol 141(June):105389; doi: 10.1016/j.yrtph.2023.105389. PMCID: PMC10436774.

Dalvi T, Nørgaard M, Fryzek JP, Movva N, Pedersen L, Hansen HP, et al. 2023. Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark. PLoS ONE 18(4):e0284037; doi: 10.1371/journal.pone.0284037. PMID: 37040387.

Thompson CM, Heintz MM, Wolf JC, Cheru R, Haws LC, Cullen JM. 2023. Assessment of mouse liver histopathology following exposure to HFPO-DA with emphasis on understanding mechanisms of hepatocellular death. Toxicol Pathol 51(1–2):4–14; doi: 10.1177/01926233231159078. PMID: 36987989.

Heintz MM, Haws LC, Klaunig JE, Cullen JM, Thompson CM. 2023. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans. Toxicol Sci 192(1):15–29; doi: 10.1093/toxic/kfad004. PMID: 36629480.

Richard AM, Lougee R, Adams M, Hidle H, Yang C, Rathman J, Magdziarz T, Bienfait B, Williams AJ, Patlewicz G. 2023. A new CSRML structure-based fingerprint method for profiling and categorizing per- and polyfluoroalkyl substances (PFAS). Chem Res Toxicol 36(3):508–534; doi: 10.1021/acs.chemrestox.2c00403. PMID: 36862450.

Carstens KE, Freudenrich T, Wallace K, Choo S, Carpenter A, Smeltz M, Clifton MS,…, Patlewicz G, et al. 2023. Evaluation of per- and polyfluoroalkyl substances (PFAS) in vitro toxicity testing for developmental neurotoxicity. Chem Res Toxicol 36(3):402–419; doi: 10.1021/acs.chemrestox.2c00344. PMID: 36821828.

Thompson CM, Proctor DM, Harris MA. 2023. Letter to “Chepelev et al. Establishing a quantitative framework for regulatory interpretation of genetic toxicity dose–response data: Margin of exposure case study of 48 compounds with both in vivo mutagenicity and carcinogenicity dose–response data.” Environ Mol Mutagen 64(4):259–260; doi: 10.1002/em.22537. PMID: 36916184.

Sterner TR, Covington TR, Mattie DR. 2023. Complex mixtures: Array PBPK modeling of jet fuel components. Toxics 11(2):187; doi: 10.3390/toxics11020187. PMID: 36851061.

Wright PSR, Briggs KA, Thomas R, Smith GF, Maglennon G, Mikulskis P, Chapman M, Greene N, et al. 2023. Statistical analysis of preclinical interspecies concordance of histopathological findings in the eTOX database. Regul Toxicol Pharmacol 138(Feb):105308; doi: 10.1016/j.yrtph.2022.105308. PMID: 36481279.

Patlewicz G, Shah I. 2023. Towards systematic read-across using Generalized Read-Across (GenRA). Comput Toxicol 25(Feb):100258; doi: 10.1016/j.comtox.2022.100258. PMID: 37693774.

Wright PSR, Smith GF, Briggs KA, Thomas R, Maglennon G, Mikulskis P, Chapman M, Greene N, et al. 2023. Retrospective analysis of the potential use of virtual control groups in preclinical toxicity assessment using the eTOX database. Regul Toxicol Pharmacol 138(Feb):105309; doi: 10.1016/j.yrtph.2022.105309. PMID: 36481280.

Houck K, Paul Friedman K, Feshuk M, Patlewicz G, Smeltz M, Clifton S, Wetmore BA, Velichko S, et al. 2023. Evaluation of 147 perfluoroalkyl substances for immunotoxic and other (patho)physiological activities through phenotypic screening of human primary cells. ALTEX 40(2):248–270; doi: 10.14573/altex.220304. PMID: 36129398.

Adams M, Hilde H, Chang D, Richard A, Williams AJ, Shah I, Patlewicz G. 2023. Development of a CSRML version of the Analog Identification Methodology (AIM) fragments and their evaluation within the Generalized Read-Across (GenRA) approach. Comput Toxicol 25(Feb):100256; doi: 10.1016/j.comtox.2022.100256. PMID: 36733411.

Wheeler MW, Lim S, House JS, Shockley KR, Bailer AJ, Fostel J, Yang L, Talley D, Raghuraman A, Gift JS. 2023. ToxicR: A computational platform in R for computational toxicology and dose–response analyses. Comp Toxicol 25(Feb):100259; doi: 10.1016/j.comtox.2022.100259. PMCID: PMC9997717.

East A, Dawson DE, Brady S, Vallero DA, Tornero-Velez R. 2023. A scoping assessment of implemented toxicokinetic models of per- and polyfluoro-alkyl substances, with a focus on one-compartment models. Toxics 11(2):163; doi: 10.3390/toxics11020163. PMID: 36851038.

Grover A, Sankaranarayanan S, Mathur V, Suri P, Qiu H, Andrews-Zwilling Y, Mease K, Taylor LK, Cahir-McFarland E, Keswani S, Yednock T. 2023. Pharmacokinetic and target engagement measures of ANX007, an anti-C1q antibody fragment, following intravitreal administration in nonhuman primates. Invest Opthalmol Visual Sci 64(2)3; 10.1167/iovs.64.2.3. PMID: 36729444.

Boyce M, Favela KA, Bonzo JA, Chao A, Lizarraga L, Moody LR, Owens EO, Patlewicz G, et al. 2023. Identifying xenobiotic metabolites with in silico prediction tools and LCMS suspect screening analysis. Front Toxicol 5(Jan 18):1051483; doi: 10.3389/ftox.2023.1051483. PMID: 36742129.